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REVIEWThe Role of Glucagon in the Pathophysiology
and Treatment of Type 2 Diabetes
Soﬁe Hædersdal, MD; Asger Lund, MD, PhD; Filip K. Knop, MD, PhD;
and Tina Vilsbøll, MD, DMScAbstract
Type 2 diabetes is a disease involving both inadequate insulin levels and increased glucagon levels. While
glucagon and insulin work together to achieve optimal plasma glucose concentrations in healthy in-
dividuals, the usual regulatory balance between these 2 critical pancreatic hormones is awry in patients
with diabetes. Although clinical discussion often focuses on the role of insulin, glucagon is equally
important in understanding type 2 diabetes. Furthermore, an awareness of the role of glucagon is essential
to appreciate differences in the mechanisms of action of various classes of glucose-lowering therapies.
Newer drug classes such as dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor ago-
nists improve glycemic control, in part, by affecting glucagon levels. This review provides an overview of
the effect of glucose-lowering therapies on glucagon on the basis of an extensive PubMed literature search
to identify clinical studies of glucose-lowering therapies in type 2 diabetes that included assessment of
glucagon. Clinical practice currently beneﬁts from available therapies that impact the glucagon regulatory
pathway. As clinicians look to the future, improved treatment strategies are likely to emerge that will either
use currently available therapies whose mechanisms of action complement each other or take advantage of
new therapies based on an improved understanding of glucagon pathophysiology.
ª 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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gen, Denmark (F.K.K.).T he opposing actions of insulin andglucagon were demonstrated nearly acentury ago.1,2 Today, the role of
glucagon is recognized as important in glucose
homeostasis and diabetes pathophysiology.3-6
Glucagon, a 29-amino acid peptide hormone,
is counterregulatory to insulin, stimulating he-
patic glucose production, thereby increasing
plasma glucose levels.7 Glucagon also stimu-
lates ketogenesis, thus working in tandem
with insulin to maintain a normal “fuel bal-
ance.”8,9 Simply put, insulin acts as a
glucose-depositing and anabolic hormone,
whereas glucagon is glucose mobilizing and
catabolic.8,10
During the past decade, the use of medica-
tions that modulate glucagon levels has gradu-
ally increased in the treatment of patients with
type 2 diabetes (T2D). Dipeptidyl peptidase-4
inhibitors (DPP-4is) and glucagon-like pep-
tide-1 (GLP-1) receptor agonists (GLP-1RAs),
which both suppress glucagon secretion, have
received increasing attention as add-on
therapies for patients with T2D.11,12 OtherMayo Clin Proc. n February 2018;93(2):217-239 n https://doi.org/1
www.mayoclinicproceedings.org n ª 2017 Mayo Foundation for Me
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glucagon secretion (either positively or nega-
tively), including sulfonylureas, exogenous in-
sulin, amylin mimetics, and sodium-glucose
cotransporter 2 inhibitors (SGLT2is).
Although plasma glucagon levels are not
used in a clinical stratiﬁcation of diabetic treat-
ment, health care providers may gain clinical
insight from understanding how glucagon
levels can be pharmacologically controlled in
patients with T2D. Of particular interest are
the abilities of glucose-lowering drugs to pre-
serve a normal counterregulatory glucagon
response in hypoglycemic conditions and,
thus, avoid hypoglycemic adverse events.
Moreover, as will be discussed, potential
beneﬁts can be gained from emerging
glucagon-modulating therapeutic strategies.
To explore the relationship between
glucagon and T2D, we performed a literature
review of glucagon and diabetes, including
glucagon in normal physiology and the patho-
physiology of T2D. We also made an extensive
effort to identify studies that assessed the effect0.1016/j.mayocp.2017.12.003
dical Education and Research. Published by Elsevier Inc. This is an open access article
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ARTICLE HIGHLIGHTS
d Under normal physiological conditions, glucagon, which is
secreted by pancreatic alpha cells, works alongside insulin to
regulate plasma glucose levels, including an increase in hepatic
glucose production and release of glucose into circulation
during hypoglycemia.
d The pathophysiology of type 2 diabetes includes aberrant
secretion of glucagon, resulting in elevated glucagon concen-
trations in both the fasting state and after a meal.
d Some glucose-lowering drug classes, including dipeptidyl
peptidase-4 inhibitors and glucagon-like peptide-1 receptor ag-
onists, decrease glucagon secretion, resulting in amelioration of
the inappropriately high glucagon concentrations characteristic
of type 2 diabetes and improvement of the insulin:glucagon
ratio.
d As clinicians consider treatment strategies for patients with type
2 diabetes, knowledge of the effect of glucose-lowering thera-
pies on glucagon can inform treatment choices.
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Downloadon glucagon of glucose-lowering drugs within
the most commonly used drug classes in
current clinical practice. We performed a
2-stage literature search for sulfonylureas, pio-
glitazone, pramlintide, DPP4-is, GLP-1RAs,
and SGLT2is: (1) search of the PubMed data-
base for names of the glucose-lowering drugs
and the terms “diabetes” and “glucagon” in the
title or abstract (restricted to English-language
articles and clinical trials in humans with no
date restriction); and (2) assessment of each
large, phase 3 clinical trial identiﬁed in articles
describing each drug’s clinical development
program to identify studies in which glucagon
levels were measured. For metformin and insu-
lin, a less extensive literature search was con-
ducted that relied primarily on mention of
glucagon results in other publications.
Although this is neither a systemic nor compre-
hensive review of all clinical studies with results
related to glucagon, the literature search did
identify an extensive number of relevant
studies.DISCOVERY OF GLUCAGON AND ITS
IMPORTANCE
Glucagon, a peptide hormone,13 was identi-
ﬁed and named in 1923 when 2 chemistsMayo Clin Proc. n February 201
ed for Anonymous User (n/a) at BS - University of Copenhagen from 
For personal use only. No other uses without permission. Copyright ©experimenting with “aqueous extracts of
pancreas” found a substance that had a hyper-
glycemic effect in dogs whose pancreas was
removed and in normal rabbits.2 Despite the
initial confusion about whether glucagon was
merely a contaminant during puriﬁcation of
insulin,1,5 researchers recognized by the
1950s that glucagon was secreted from
pancreatic alpha cells,14 thus establishing the
existence of 2 distinct pancreatic hor-
mones,15,16 both responsive to plasma glucose
levels.16 In 1975, Unger and Orci9 proposed a
“bihormonal hypothesis” of diabetes on the
basis of evidence that the metabolic effects of
T2D result from absolute or relative hyperglu-
cagonemia, as well as absolute or relative insu-
lin deﬁciency.9 The authors further suggested
that controlling glucagon secretion could
potentially improve the treatment of diabetes.9
A substantial body of evidence suggests that
hyperglucagonemia contributes to the hypergly-
cemic state of patients with T2D.17-20 Although
themechanisms behinddiabetic hyperglucagone-
mia and to what extent it affects the T2D state
remain to be elucidated, studies with transgenic
mice provide insight into the role of glucagon
and its receptor. Transgenic mice lacking the
glucagon receptor do not develop diabetes, even
after nearly-complete beta-cell destruction.21,22
However, this ﬁnding has not been conﬁrmed
by other groups.23 Furthermore, transgenic
mice with defective leptin receptors develop the
phenotype of severe T2D, whereas transgenic
mice defective in both glucagon and leptin recep-
tors do not.24 Adenoviral reintroduction of the
glucagon receptor in these leptin receptore and
glucagon receptoredeﬁcient mice resulted in
severe hyperinsulinemia and hyperglycemia.24
ROLE OF GLUCAGON IN HEALTHY
INDIVIDUALS
Normal glucose homeostasis depends largely on
balanced secretion of glucagon and insulin from
pancreatic alpha and beta cells, respectively, in a
tightly regulated, multiloop feedback system
(Figure).7,25 Following a meal, high plasma
glucose levels (hyperglycemia) stimulate the
pancreas to release insulin. Insulin promotes
glucose uptake and use by insulin-dependent
tissues, stimulates formation of glycogen from
glucose (glycogenesis) in the liver and muscle,
and suppresses glucagon secretion.7,25 When
plasma glucose levels fall too low8;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
www.mayoclinicproceedings.org
ClinicalKey.com by Elsevier on January 29, 2019.
2019. Elsevier Inc. All rights reserved.
FIGURE. Regulation of blood glucose levels by glucagon and insulin in healthy individuals. In healthy in-
dividuals, glucagon and insulin work together to maintain normal plasma glucose levels. During hyper-
glycemia, pancreatic beta (b) cells release insulin, which stimulates glucose uptake by energy-consuming
cells and the formation of glycogen in the liver. During hypoglycemia, pancreatic alpha (a) cells release
glucagon, which stimulates gluconeogenesis and glycogenolysis in the liver and the release of glucose to
the plasma.
ROLE OF GLUCAGON IN TYPE 2 DIABETES
Mayo Clin Proc. n February 2018;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
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TABLE 1. Factors Regulating Glucagon Secretion43
Stimulatory factors Inhibitory factors
Hypoglycemia Carbohydrate meal
Stress Glucose
Protein meal Isoleucine10
Most amino acids Nonesteriﬁed fatty acids
Some fatty acids10 Ketones
Parasympathetic nerves Gamma-aminobutyric acid10
Sympathetic nerves Adenosine triphosphate
Pituitary adenylate cyclaseeactivating polypeptide Zinc3,10
Cold exposure44
Stimulatory hormones Inhibitory hormones
Adrenaline (epinephrine) Amylin10
Cholecystokinin Glucagon-like peptide-1
Gastrin-releasing peptide Insulin
Ghrelin45 Leptin46,47
Glucose-dependent insulinotropic polypeptide48 Secretin
Oxytocin Somatostatin
Vasoactive intestinal peptide
Vasopressin
Adapted from Diabetologia,43 with permission of Springer.
MAYO CLINIC PROCEEDINGS
220
Download(hypoglycemia), the pancreas releases glucagon.
Upon reaching the liver, glucagon promotes
breakdown of glycogen to glucose (glycogenol-
ysis), promotes glucose synthesis (gluconeogen-
esis), inhibits glycogen formation (glycogenesis),
and thusmobilizes export of glucose into the cir-
culation. Thus, glucagon provides a critical
response to hypoglycemia. Interestingly, our
group recently demonstrated that glucagon is
also secreted in patients who have undergone to-
tal pancreatectomy, demonstrating extrapancre-
atic secretion of glucagon in humans.26 The
potential implications of this ﬁnding for the
treatment of T2D are discussed below, though
open questions remain: Is extrapancreatic secre-
tion primarily mediated by enteroendocrine
cells? Does it occur in both healthy individuals
and patients with T2D? Is its metabolic effect
physiologically relevant?
Glucagon’s physiological role is broader
than as a direct counterregulatory hormone to
insulin. Glucagon also plays a role in lipidmeta-
bolism,27-31 inﬂuences food intake, affects body
weight, promotes autophagy, and has pleio-
tropic effects on the cardiovascular system.3
Notably, many of these glucagon functions are
associated with physiological processes awry
in T2D. Increasingly, glucagon is recognized
for its role in amino acid metabolism32 throughMayo Clin Proc. n February 201
ed for Anonymous User (n/a) at BS - University of Copenhagen from 
For personal use only. No other uses without permission. Copyright ©its regulation of hepatic ureagenesis,33 alter-
ation of transcription of key enzymes in the
urea cycle,28,34,35 and a probable indirect inﬂu-
ence on alpha-cell mass.36,37
In humans, pancreatic islets are composed
of approximately 40% alpha and 60%beta cells,
whereas the relative proportions in mouse islets
are approximately 20% and 80%, respectively,
hinting at the relative importance of glucagon
secretion.10,38 An altered alpha- to beta-cell
ratio may be a contributing factor in T2D path-
ogenesis.39,40 Interestingly, glucagon receptor
antagonism is associated with alpha-cell prolif-
eration,36 and there is much current interest in
transdifferentiation of beta cells from alpha
cells.39,41,42 In the human pancreas, alpha and
beta cells are spatially intermixed, which has
important physiological implications because
glucagon’s effects on insulin-producing beta
cells may occur, at least partially, in a paracrine
manner.38 The relative hyperglucagonemia of
diabetes resulting from an altered alpha- to
beta-cell ratio might be a consequence of beta-
cell dedifferentiation to glucagon-producing
islet cells, greater beta-cell susceptibility to cell
apoptosis, and alpha-celleresistant mecha-
nisms to cellular stress.42
Various factors and hormones modulate
glucagon secretion from the pancreatic alpha
cell (Table 1).3,10,43-48 They may be either
stimulatory or inhibitory and involve multiple
physiologic pathways. The GLP-1 inhibition of
glucagon secretion is particularly noteworthy,
because the GLP-1RA class of glucose-
lowering drugs mimics the effects of GLP-
1.49,50 Together, these factors regulate
glucagon secretion to prevent the potentially
lethal state of hypoglycemia.43
The insulin-glucagon interaction is impor-
tant in energy homeostasis in the entire body:
(1) a high insulin:glucagon ratio promotes
biosynthesis of proteins, inhibits glucose
production, and reduces release of free fatty
acids, whereas (2) a low insulin:glucagon ratio
helps the body access stored nutrients, in-
creases hepatic glucose production from
glycogen and amino acids, and promotes the
breakdown of adipose tissue into free fatty
acids and glycerol.8 Kalra and Gupta51 called
the insulin:glucagon ratio a “physiological
fulcrum,” balancing the 2 opposite ends of
the metabolic spectrum to conserve energy if
possible, but provide it when needed.8;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
www.mayoclinicproceedings.org
ClinicalKey.com by Elsevier on January 29, 2019.
2019. Elsevier Inc. All rights reserved.
ROLE OF GLUCAGON IN TYPE 2 DIABETESThe insulin:glucagon ratio determined by
measurement of plasma glucagon levels may
vary from the portal insulin:glucagon ratio,
and conclusions on peripheral measures
should always be approached with caution
because of higher insulin and glucagon con-
centrations in portal circulation compared
with peripheral.3 Modest changes in insulin
and/or glucagon secretion lead to ampliﬁed re-
sponses on glucose metabolism, in part
because of the portal insulin:glucagon ratio.
Thus, this provides a strong physiological
argument for the rationale of targeting
glucagon secretion.
Although studies have not established the
utility of measuring glucagon routinely in clin-
ical practice, the insulin:glucagon ratio is a
comprehensive metabolic index that has been
used for many years in research. Understand-
ing how different drug classes interact with
glucagon and how they inﬂuence the
insulin:glucagon ratio can help to explain the
efﬁcacy and safety proﬁles of such drugs and
inform the clinician’s choice of treatment agent
or potential combinations of treatments.51
ROLE OF GLUCAGON IN THE PATHOPHYS-
IOLOGY OF T2D
In patients with T2D, regulation of glucagon
secretion is ﬂawed, with elevated plasma
glucagon concentrations in the fasting state
and defective postprandial glucagon suppres-
sion that results in undesirably high plasma
glucagon concentrations in the context of
hyperglycemia.4,6,52,53 Thus, hyperglucagone-
mia contributes to the increased hepatic
glucose output characterizing patients with
T2D.4,43,54 Furthermore, in patients with
T2D, plasma glucagon concentrations may
even increase in response to a meal.55
Although the mechanisms responsible for
elevated glucagon levels in patients with T2D
under hyperglycemic conditions are not fully
understood, one theory is that pancreatic
alpha cells are resistant to the glucagon-
suppressive effects of glucose and insulin.4,10
Mechanisms underlying hyperglucagone-
mia in T2D remain to be fully elucidated. Inter-
estingly, hyperglucagonemia in T2D is
aggravated by oral glucose intake but not by
intravenous glucose administration, which re-
sults in signiﬁcant glucagon suppression.56,57
This suggests that factors originating fromMayo Clin Proc. n February 2018;93(2):217-239 n https://doi.org/1
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Unive
For personal use only. No other uses withounutrient stimulation of the gastrointestinal tract
may play an important role. The recent conﬁr-
mation that glucagon can be secreted from
extrapancreatic tissues constitutes an interesting
explanation of the postprandial hyperglucago-
nemia observed in T2D, namely, that postpran-
dial glucagon production may be gut-derived,
not originating from the pancreas.26
An interesting aspect of glucagon patho-
physiology in T2D with therapeutic implica-
tions is the dynamic nature of the glucagon
response to and regulation of both hypoglyce-
mia and hyperglycemia. As will be discussed
further below, therapeutic agents shown to
have a short-term effect on postprandial
glucagon levels (w180 minutes) may not be
equally effective over longer treatment periods.
RELEVANCE OF GLUCAGON TO TREAT-
MENT OF T2D AND EFFECTS OF GLUCOSE-
LOWERING THERAPIES ON GLUCAGON
Because glucagon has a central role in glucose
homeostasis7 and patients with T2D have
glucagon-mediated elevated hepatic glucose
production,43,54 addressing the fasting and post-
prandial hyperglucagonemia of patients with
T2D has emerged as an interesting strategy for
existing and future glucose-lowering thera-
pies.17,19 The introduction of new drug classes
that modulate glucagon has underscored the
limited attention previously shown to older
drug classes in this regard. Table 254,58-168 sum-
marizes the effects of the major classes of
glucose-lowering drugs on fasting and postpran-
dial glucagon levels and reports results of less
common glucagon assessments, such as those
under experimentally induced hypoglycemia.
Older Agents
In general, older therapies have been studied less
extensively than newer drug classes regarding ef-
fects on glucagon secretion; however, the effect of
glucose-lowering drugs on glucagon secretion is
becoming more apparent as research in this area
expands. In studies with older therapies, results
regarding glucagon are often inconsistent, which
may be a consequence of variability in study
design. Furthermore, the difﬁculties associated
with measuring glucagon should be recognized.
Glucagon assays have evolved over time with
inconsistencies in both sensitivity and speciﬁcity,
complicating cross-study comparisons.169 Cross-
reaction with other glucagon-like peptides has0.1016/j.mayocp.2017.12.003 221
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TABLE 2. Summary of Studies Identiﬁed That Assess the Effect of Glucose-Lowering Therapies on Glucagon in Patients With Type 2 Diabetesa
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
Older agents
Biguanides Metforminc 2 Large studies58,59
2 Small studies60,61
Signiﬁcant decrease vs BL58
Decrease vs BL at 52 wk;
no effect at 26 wk59
Increase vs PBO60
No effect58 Decrease in glucagon vs BL
after administration of
oral or IV glucose60
Increase in 12-h plasma
glucagon vs
glimepiride61
None
Insulin Exogenous insulinc 4 Small studies62-65 NR NR No effect on glucagon
response to arginine
stimulation65
Decrease in glucagon after
arginine stimulation vs
pretreatment64
Decrease in plasma
glucagon after IV
administration of
insulin þ glucose to
fasting patients63
Signiﬁcant decrease in 48-h
plasma glucagon in
insulin-optimized period
compared with
“uncontrolled” period62
None
SU Glyburide/glibenclamide 5 Small studies66-71 NR No effect after an OGTT70
Nonsigniﬁcant increase
after meal71
No effect vs PBO68
No effect on plasma
glucagon (2 studies)68,69
No effect on 24-h plasma
glucagon67
Suppressed glucagon
secretion during
hypoglycemia66
Exerts an inhibitory effect
on glucagon-producing
alpha cells72
SU Glipizide 1 Large study58
4 Small studies68,73-75
No effect58
Signiﬁcant increase vs BL73
No effect58
No effect vs PBO68
Signiﬁcant increase after
liquid meal challenge73
No difference in plasma
glucagon during
hyperglycemic clamp75
No effect on plasma
glucagon68
Elevated plasma glucagon74
None
Continued on next page
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TABLE 2. Continued
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
Older agents, continued
SU Gliclazidec 7 Small studies70,76-81 NR No effect after
an OGTT70
No effect on plasma
glucagon78,80
No effect during IV glucose
tolerance test or
arginine test76
No effect on plasma
glucagon or in OGTT77
Signiﬁcant decrease in
plasma glucagon during
hyperinsulinemic pulse79
No effect on plasma
glucagon during glucose
infusion81
None
SU Glimepiride 4 Large studies54,82-84
4 Small studies61,85-88
No effect
(4 studies)83,85,86,88
Increase from BL82
Increase from BL
(2 studies)54,86
No effect87
Decreased 12-h plasma
glucagon vs metformin61
No effect on plasma
glucagon84
Signiﬁcant increase in
glucagon vs BL after
arginine stimulation
test88
None
TZD Pioglitazone (Actos) 1 Large study89
1 Small study90
No effect90 No effect
(2 studies)89,90
None reported None
Amylin mimetics
Amylin mimetic Pramlintide (Symlin) 1 Small study91 NR Decrease91 None reported Suppresses glucagon
secretion; reduces
postprandial rise in
glucagon92
Continued on next page
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TABLE 2. Continued
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
DPP-4is
DPP-4i Sitagliptin (Januvia) 3 Large studies89,93,94
4 Medium studies95-98
6 Small studies60,88,99-102
Decrease relative to BL94
No effect (2 studies)60,88
Signiﬁcant decrease vs
PBO (4 studies)89,93,96,98
Signiﬁcant decrease vs BL
(2 studies)97,100
Decrease, but not vs
PBO60
Decrease, but less than
with exenatide twice a
day95
No change when added to
liraglutide102
No effect99
No signiﬁcant change after
hyperglycemic clamp101
Nonsigniﬁcant decrease
during isoglycemic
clamp98
Lowers glucagon secretion
from pancreatic alpha
cells
Decreases glucagon levels
in circulation in a
glucose-dependent
manner
After a meal, results in
decreased glucagon
concentrations103
DPP-4i Vildagliptind (Galvus/
Zomelis)
5 Large studies54,84,104-106
10 Small studies87,107-115
No difference vs PBO
(4 studies)105,109,111,113
Decrease104
Signiﬁcant decrease
vs PBO (8
studies)105-107,
109-111,113,114
Signiﬁcant decrease vs
BL108
Signiﬁcant decrease vs
glimepiride54
Decrease vs BL
Increase, but less than
PBO112
Increased glucagon during
hypoglycemic clamp107
No difference vs PBO
during hypoglycemic
clamp112
Decreased plasma
glucagon84
No difference in AUC0-24
between AM and PM
dosing; results similar to
PBO115
Makes pancreas produce
less glucagon; enhanced
insulin:glucagon ratio
during hyperglycemia;
enhances the sensitivity
of alpha cells to glucose,
resulting in more
glucose-appropriate
glucagon secretion116
DPP-4i Saxagliptin (Onglyza) 6 Large studies117-122
1 Small study123
NR Signiﬁcant decrease vs
PBO (2 studies)119,122
Decrease vs PBO121
Decrease vs glyburide118
No effect117,120
Signiﬁcant decrease vs
PBO during IV oral
hyperglycemic clamp;
decrease during IV
hyperglycemic clamp but
not signiﬁcant vs PBO123
Decreases glucagon after a
meal; lowers glucagon
secretion from
pancreatic alpha cells124
DPP-4i Linagliptin (Tradjenta/
Trajenta)
1 Large study125
2 Small studies86,126
No effect86 Decrease (both peak
postprandial excursion
and area under
curve)125
Decrease vs BL86
Increase during
hypoglycemia, but not vs
PBO126
Lowers glucagon secretion
Decreases level of
glucagon in
circulation127
Continued on next page
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TABLE 2. Continued
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
DPP-4is, continued
DPP-4i Alogliptin (Nesina) 2 Large studies128,129
2 Medium studies130,131
1 Small study132
No effect (2 studies)128,132 Signiﬁcant decrease
vs PBO
(3 studies)128,130,131
Decrease vs BL, but not
signiﬁcant vs PBO129
None reported Decreases postprandial
glucagon133
GLP-1RAs
GLP-1RA
(short acting)
Exenatide twice a day
(Byetta)
4 Large studies134-137
2 Medium studies95,97
6 Small studies88,138-142
Decrease vs BL
(2 studies)136,137
No effect (2 studies)88,140
No difference vs insulin
(2 studies)135,141
Signiﬁcant decrease
vs PBO
(3 studies)138,139,142
Signiﬁcant decrease vs BL
(2 studies)95,97
Signiﬁcant decrease vs
sitagliptin (2 studies)95,97
Signiﬁcant reduction vs
insulin glargine
postbreakfast, signiﬁcant
increase postlunch141
No effect140
Decreased plasma
glucagon134
Suppresses inappropriately
elevated glucagon
secretion
Lowers serum glucagon
concentrations during
periods of
hyperglycemia
Does not impair normal
glucagon response to
hypoglycemia143
GLP-1RA
(short acting)
Lixisenatide (Adlyxin/
Lyxumia)
2 Large studies144,145
2 Small studies146,147
Decrease vs BL145 Signiﬁcant decrease vs
PBO145
Signiﬁcant decrease vs
liraglutide144
No effect on glucagon
suppression after IV
glucose challenge vs
PBO145
Signiﬁcant decrease vs
PBO at 3.5 mmol/L
glucose; no difference vs
PBO at 2.8 mmol/L
glucose146
Decreases glucagon
secretion
Decreases postprandial
glucagon148
GLP-1RA
(long acting)
Exenatide QW
(Bydureon)
1 Large study136 Decrease vs BL136
Signiﬁcant decrease vs
exenatide twice a day
NR None reported Suppresses inappropriately
elevated glucagon
secretion
Moderates glucagon
secretion and lowers
serum glucagon
concentrations during
periods of
hyperglycemia
Does not impair normal
glucagon response to
hypoglycemia149
Continued on next page
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TABLE 2. Continued
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
GLP-1RAs, continued
GLP-1RA
(long acting)
Liraglutide (Victoza) 7 Large
studies82,85,137,144,150-152
1 Medium study153
5 Small studies126,154-157
No effect (2 studies)85,150
Signiﬁcant decrease vs BL82
Decrease vs BL137
Decrease vs BL, but not
signiﬁcant vs PBO152
Signiﬁcant decrease vs
PBO151
Signiﬁcant decrease vs
PBO at wk 12, but not
signiﬁcant at subsequent
visits153
Signiﬁcant decrease vs
PBO (2 studies)155,156
Decrease vs BL144
Signiﬁcant reduction in
incremental ratio of
postprandial plasma
glucagon to BL plasma
glucagon, but no effect
on postprandial plasma
glucagon157
Increase during
hypoglycemic clamp126
Increase after OGTT at 12
wk but not sustained at
wk 24, 36, or 48;
delayed time to peak
glucagon response153
Signiﬁcant decrease vs
PBO in 24-h glucagon154
Decreases glucagon in a
glucose-dependent
manner. A single dose of
liraglutide did not impair
glucagon response to
low glucose
conditions158
GLP-1RA
(long acting)
Albiglutide
(Tanzeum/Eperzan)
1 Large study159
1 Small study160
No effect159 Decrease, but not
signiﬁcant vs PBO159
Signiﬁcant increase vs PBO
during hypoglycemia
(glucose clamp 3.3
mmol/L [59.4 mg/dL]);
no effect vs PBO during
glucose clamp 9.0
mmol/L (162 mg/dL)160
Single dose did not impair
glucagon response to
low glucose
concentrations161
GLP-1RA
(long acting)
Dulaglutide (Trulicity) 2 Large studies59,162 Numeric decrease vs BL;
no difference vs insulin
glargine162
Signiﬁcant decrease vs
metformin at 26 wk;
decrease vs BL, but no
difference vs metformin
at 52 wk59
NR None reported Decreases glucagon
secretion
Decreases fasting
glucagon163
GLP-1RA
(long acting)
Semaglutide (FDA
marketing application
ﬁled Dec 2016)
1 Large study164 Signiﬁcant decrease vs
PBO164
NR None reported Not available
Continued on next page
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TABLE 2. Continued
Drug class Drug No. of studiesb
Effect on
fasting glucagon
Effect on postprandial
glucagon
Additional glucagon
measures
Mention in
label (PI or SPC)
SGLT2is
SGLT2i Canagliﬂozin (Invokana) No studies identiﬁed None
SGLT2i Dapagliﬂozin (Farxiga/
Forxiga)
1 Large study117
3 Small studies165-167
Signiﬁcant increase vs
BL (2 studies)166,167
Increase vs BL
(2 studies)117,165
Signiﬁcant increase in
fasting glucagon vs PBO
during euglycemic
hyperinsulinemic clamp
(2 studies)166,167
Signiﬁcant increase in
fasting glucagon:insulin
ratio vs BL or PBO
(2 studies)166,167
None
SGLT2i Empagliﬂozin (Jardiance) 1 Medium study168 Increase vs BL after single
dose168
Nonsigniﬁcant increase vs
BL after 4-wk
treatment168
Signiﬁcant increase vs BL
after single dose and
after 4- wk treatment168
Decrease in
insulin:glucagon ratio
after single dose and
after 4-wk treatment vs
BL168
None
aAUC0-24 ¼ area under curve from time 0 to 24 h; BL ¼ baseline; DPP-4i ¼ dipeptidyl peptidase-4 inhibitor; FDA ¼ Food and Drug Administration; GLP-1RA ¼ glucagon-like peptide-1 receptor agonist; IV ¼ intravenous;
NR ¼ not reported; OGTT ¼ oral glucose tolerance test; PBO ¼ placebo; PI ¼ prescribing information; QW ¼ once weekly; SGLT2i ¼ sodium-glucose cotransporter 2 inhibitor; SPC ¼ summary of product characteristics;
SU ¼ sulfonylurea; TZD ¼ thiazolidinedione.
bLiterature search for metformin and insulin was less extensive than for other drugs.
cLarge studies have N100, medium studies N¼50 to N<100, and small studies N<50.
dNot marketed in the United States.
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Downloadbeen especially challenging regarding speciﬁcity,
and many assays have not been sensitive enough
to detect glucagon levels of less than 10 pmol/
L.169 The study design, lack of studies with older
agents and glucagon as a primary end point, and
the recognition of unreliable older glucagon as-
says make it difﬁcult to determine the contribu-
tion of the effect of glucagon to the overall
pharmacologic proﬁle of the drug.
Metformin has been in use for decades, yet
its mechanism of action is not fully under-
stood. As summarized in Table 2, the effect
of metformin on glucagon levels varies widely
across clinical studies.58-61 The primary action
of metformin is to decrease hepatic glucose
production; this contrasts with the physiologic
action of glucagon to stimulate gluconeogen-
esis in the liver.170,171 The overall glucose-
lowering effect of metformin is, at least in
part, the result of its inhibition of glucagon-
induced stimulation of gluconeogenesis rather
than its effect on the levels of glucagon or ac-
tion on insulin.172 An important murine study
demonstrated that metformin acts to antago-
nize glucagon by affecting the cyclic adenosine
monophosphate pathway in hepatocytes,173 a
ﬁnding that has generated much interest in
revisiting the mechanism of metformin.
Exogenous insulin is widely used to treat
T2D; however, its effects on glucagon levels
have not been studied extensively in humans.
Although endogenous insulin suppresses
glucagon secretion under normal physiologic
conditions, the molecular mechanisms of its
action are not fully understood.174 In small
mechanistic studies from the 1970s, exoge-
nous insulin was shown to decrease plasma
glucagon levels in patients with T2D.62-64
The primary mechanism of action of sulfo-
nylureas is to increase insulin secretion through
effects on beta cells.171 Based on their mecha-
nism of action, a direct effect of sulfonylureas
on pancreatic glucagon secretion would not be
expected; the bulk of studies examining
glucagon secretion are consistent with this view
(Table 2).58,67-70,75-78,80,81,83-85 However, sulfo-
nylureas did increase fasting and/or postprandial
glucagon levels in some studies,54,71,73,74,82,86
while decreasing it in 3 others.61,66,79 However,
in most of the sulfonylurea studies listed in
Table 2, measurement of glucagon was not the
primary aim of the study, sulfonylurea was often
the comparator to another therapy that was theMayo Clin Proc. n February 201
ed for Anonymous User (n/a) at BS - University of Copenhagen from 
For personal use only. No other uses without permission. Copyright ©focus of the study, and any sulfonylurea effects
on glucagon that did occur were not interpreted
as pharmacologically signiﬁcant.
Finally, among older agents, pioglitazone,
the only thiazolidinedione widely marketed
globally, did not have an effect on either fast-
ing or postprandial glucagon concentrations in
2 studies that measured glucagon.89,90
Amylin Mimetics
Pramlintide, the only amylin mimetic mar-
keted in the United States, decreases postpran-
dial glucagon responses.91,92,175 This is not
unexpected because the hormone amylin
inhibits glucagon secretion.10,175
DPP-4is
The DPP-4i and GLP-1RA (discussed later)
drug classes have been studied to a greater
extent regarding their effects on glucagon
than the older drug classes because their effects
in this regard are widely recognized.12,51,171
The DPP-4is are “incretin enhancers” that
prevent the degradation of endogenously
produced glucose-dependent insulinotropic
polypeptide and GLP-1, thus extending their ac-
tion. The GLP-1 is a gut incretin hormone that
stimulates pancreatic beta cells to secrete insulin
and also suppresses glucagon secretion from the
pancreatic alpha cells.176 Preclinical studies
showed that GLP-1 inhibits glucagon release
enough to inﬂuence physiological glucose regu-
lation.43 Supraphysiological doses of native
GLP-1 can restore alpha-cell glucose sensitivity
in patients with T2D, facilitating a strict
glucose-dependent inhibition of glucagon secre-
tion.177 Thus, GLP-1 suppresses glucagon secre-
tion during hyperglycemia, with no major role
during hypoglycemia. Interestingly, the other
incretin hormone, glucose-dependent insulino-
tropic polypeptide, increases glucagon secretion
duringhypoglycemic and euglycemic conditions
but not during hyperglycemia.178-180 Conse-
quently, DPP-4is would suppress glucagon
secretion during hyperglycemia but not impair
glucagon response to hypoglycemia.126
BothDPP-4is andGLP-1RAs exert inhibitory
actions on glucagon-producing alpha cells that
may be, at least partially, responsible for their
role in ameliorating T2D. The DPP-4 is
expressed in pancreatic islets, almost exclusively
in alpha cells in the human pancreas.181,182 The
DPP-4 localization to alpha cells suggests a direct8;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
www.mayoclinicproceedings.org
ClinicalKey.com by Elsevier on January 29, 2019.
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ROLE OF GLUCAGON IN TYPE 2 DIABETESeffect on alpha cells, implying a paracrine effect
on insulin-producing beta cells. Human islets
treated with the DPP-4i vildagliptin secreted
higher levels of GLP-1 and insulin; thus, the in-
hibition of islet DPP-4 activity may contribute to
the insulinotropic and glucose-lowering action
of DPP-4is.182 Likewise, a local GLP-1 system
may exist in human pancreatic islets, with alpha
cells containing GLP-1 and the enzyme prohor-
mone convertase 1/3, which has a role in both
glucagon and insulin biosynthesis.183
In clinical studies, DPP-4is, including sita-
gliptin, vildagliptin, saxagliptin, linagliptin, and
alogliptin, consistently decrease postprandial
glucagon secretion compared with the usual
glucagon response to ameal, with either no effect
or a slightly decreased effect on fasting glucagon
(Table 2). Unsurprisingly, given the glucose-
dependent effect of the incretin hormones,
DPP-4is are glucose dependent in both their
action on insulin and glucagon secretion.11
As alluded to earlier, DPP-4is do not affect
the normal counterregulatory responses to
hypoglycemia.11 In patients with T2D, the
normal counterregulatory response to
hypoglycemia is impaired because of the hyper-
glucagonemic characteristic of T2D.4 Thus, a
therapeutic challenge is to reduce glucagon
levels when necessary but, in doing so, not to
disrupt the normal, appropriate increase in
glucagon in response to hypoglycemia. The
effects of DPP-4is on these counterregulatory
pathways have been explored in clinical studies
that used a “hypoglycemic clamp” to hold
plasma glucose at a low target concentration
(often by the addition of intravenous insu-
lin).107,126 A hypoglycemic clamp study with
linagliptin demonstrated no disruption of
normal counterregulatory responses to hypo-
glycemia in patients with T2D.126 In contrast,
a study of vildagliptin suggests that alpha-cell
response to hypoglycemia may even be
enhanced by treatment with a DPP-4i.107
Protection of the counterregulatory response
to hypoglycemia may, in part, provide a mech-
anistic explanation for the low risk of hypogly-
cemia that is characteristic of both the DPP-4i
and GLP-1RA drug classes.107,184
GLP-1RAs
The GLP-1RAs are peptides that act as “incre-
tin mimetics” to increase GLP-1 receptor
signaling. They increase postprandial insulinMayo Clin Proc. n February 2018;93(2):217-239 n https://doi.org/1
www.mayoclinicproceedings.org
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start to rise), inhibit glucagon secretion, slow
gastric emptying, and induce satiety. Like
DPP-4is, GLP-1RAs are glucose dependent in
their action on insulin secretion and their
glucagonostatic effect.4,11,12
Clinical studies have generally demonstrated
that, similar to DPP-4is, GLP-1RAs substantially
lower glucagon concentrations in both the fast-
ing state and after ameal (Table 2), thus reducing
the hyperglucagonemia of T2D. Early studies
with exenatide twice daily (the ﬁrst drug mar-
keted in this class) and liraglutide demonstrated
reduced postprandial glucagon concentrations
in patients with T2D.138,139,154 These results
have since been conﬁrmed in other mechanistic
studies and large clinical trials across the GLP-
1RA class. Exenatide twice daily, lixisenatide,
exenatide once weekly, liraglutide, and dulaglu-
tide all decrease glucagon secretion.59,82,136-
139,142-146,148,149,151-158,162,163,171 In addition,
semaglutide, a GLP-1RA still in clinical develop-
ment, decreased fasting glucagon levels in a
study.164
Although GLP-1RAs generally decrease
glucagon levels, results are not uniform across
the drug class. This may be a consequence of
GLP-1RA class members differing in both struc-
ture and pharmacokinetic proﬁle. Albiglutide, a
large (>600 amino acid) peptide, does not
appear to signiﬁcantly decrease postprandial
glucagon, compared with placebo, or to affect
the magnitude of the glucagon response in hy-
poglycemia,159,160 likely because it is too large
to enter the central nervous system. However,
albiglutide affected the timing of the glucagon
response to hypoglycemia in a study.160
Interestingly, long-term treatment (48
weeks) with liraglutide in the Liraglutide and
Beta-cell Repair (LIBRA) trial resulted in an in-
crease in glucagon after an oral glucose tolerance
test.153 Although glucagon enzyme-linked
immunosorbent assay cross-reaction with other
glucagon-like peptides might possibly
contribute to this, the mechanism for this
unexpected observation remains unclear and
warrants additional study.
In patients with T2D, the glucagon-
suppressive effect of GLP-1RAs likely contributes
approximately one-third of the overall glucose-
lowering effect.50,185 Decreased glucagon levels
with GLP-1RA treatment result in an increased
insulin:glucagon ratio.139,153,154 Interestingly, in a0.1016/j.mayocp.2017.12.003 229
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Downloadstudy comparing the short-term effects of the GLP-
1RA exenatide twice daily and the DPP-4i sitaglip-
tin, patients treated with exenatide twice daily had
signiﬁcantly lower postprandial glucagon levels
than those treated with sitagliptin.95 Overall,
most studies on the glycemic contribution of the
glucagon-lowering ability of GLP-1RAs are based
on short-term effects, whereas data on chronic
effects of GLP-1RAs on glucagon suppression are
scarce and need to be investigated further.
The effects of GLP-1RA on the physiological
counterregulatory response during hypoglyce-
mia have been explored in clinical studies using
a hypoglycemic clamp, similar to the studies
described for DPP-4is. These studies demon-
strated no disruption of normal counterregula-
tory responses to hypoglycemia in patients
with T2D by GLP-1RAs, including lixisena-
tide,186 albiglutide,160 and liraglutide.126 In
addition, exenatide did not disrupt these
responses in healthy volunteers.184 In summary,
GLP-1RAs decrease inappropriately elevated
glucagon levels but do not impair the counterre-
gulatory response of glucagon to hypoglycemia.
SGLT2is
The SGLT2i class of glucose-lowering drugs pre-
vents reabsorption of glucose in the kidney,
which facilitates the excretion of glucose in urine
and, in turn, reduces plasma glucose
levels.171,187 Because these actions are insulin
independent, there is minimal potential for
hypoglycemia.187 Results from clinical studies
examining the effects of treatment with dapagli-
ﬂozin117,165-167 and empagliﬂozin168 on
glucagon secretion demonstrated increased fast-
ing glucagon and postprandial glucagon
levels and decreased insulin:glucagon ratios. To
our knowledge, no clinical studies have
reported the effects of canagliﬂozin on glucagon
(Table 2).
Although there is limited information in
humans regarding whole-body metabolic adap-
tation to treatment with SGLT2is,188 2 inde-
pendent research teams uncovered an
apparent SGLT2i class effect. Although
SGLT2is lower fasting glucose in patients
with T2D, they elicit a paradoxical rise in
endogenous glucose production.167,168 Merovci
et al167 found that dapagliﬂozin induced
glucosuria and improved peripheral insulin
sensitivity; however, endogenous glucose
production increased substantially and wasMayo Clin Proc. n February 201
ed for Anonymous User (n/a) at BS - University of Copenhagen from 
For personal use only. No other uses without permission. Copyright ©accompanied by an increase in fasting plasma
glucagon concentration. In the other study,
Ferrannini et al168 reported that patients
exhibited glycosuria after empagliﬂozin treat-
ment, but empagliﬂozin was also associated
with increased endogenous glucose production,
beta-cell glucose sensitivity, and postprandial
glucagon response.168 Notably, studies
measuring glucagon are often of short duration
and may not provide insight into longer-term
glucagon effects. In the Ferrannini et al study,
the magnitude of the glucagon increase after 4
weeks of treatment was decreased compared
with the increase after a single dose.168
Thus, it appears that SGLT2is may have a
direct effect on glucagon in T2D. Merovci
et al167 speculate on several potential mecha-
nisms for the relative increase in glucagon after
SGLT2i treatment: acute decline in insulin-
induced plasma glucose concentration from
one hyperglycemic level to a lower hyperglyce-
mic level; activation of a neural reﬂex that con-
nects the kidney directly with pancreatic alpha
cells; or activation of neuronal centers in the
central nervous system that communicate
with the alpha cells.167 Two mechanistic
studies provide insight into the increase in
glucagon secretion with SGLT2i treatment
via a direct effect on SGLT2 expression found
in pancreatic alpha cells.189,190 The SGLT2is
have been associated with an increased
risk of diabetic ketoacidosis.191 The
SGLT2i-induced increase in glucagon may
provide a partial explanation for this observa-
tion given that increased levels of glucagon are
linked with diabetic ketoacidosis.192FUTURE OF DIABETES TREATMENT
RELATED TO GLUCAGON
On the basis of ﬁndings described above,
Merovci et al,167 among others, have suggested
that the combination of an SGLT2i and an
incretin-based therapy could provide a potential
synergism for the treatment of patients with
T2D.51,167,193,194 The rationale is that the
incretin-based drug would block the increased
production of endogenous glucose and elevated
glucagon levels associated with SGLT2is and
enhance the glucose-lowering effect of the
SGLT2i.167,193 A number of studies have
reported a reduction in glucose (glycated hemo-
globin [A1C]) levels after treatment with the8;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
www.mayoclinicproceedings.org
ClinicalKey.com by Elsevier on January 29, 2019.
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TABLE 3. Randomized Phase 3 Clinical Studies That Combine Either a DPP-4i or a GLP-1RA With an SGLT2i in the Treatment of Type 2 Diabetesa
Reference, year Duration to end point
Background
therapy Treatment arms n
Change from
baseline in A1C (%) [mmol/mol]b
DPP-4i þ SGLT2ic
Lewin et al,195 2015 24 wk None Linagliptin 5 mg þ empagliﬂozin 10 mg 135 1.24  0.06 [13.6  0.7]
Linagliptin 5 mg þ empagliﬂozin 25 mg 134 1.08  0.06 [11.8  0.7]
Linagliptin 5 mg 133 0.67  0.06 [7.3  0.7]
Empagliﬂozin 10 mg 132 0.83  0.6 [9.1  0.7]
Empagliﬂozin 25 mg 133 0.95  0.06 [10.4  0.7]
DeFronzo et al,196 2015 24 wk Metformin Linagliptin 5 mg þ empagliﬂozin 10 mg 135 1.08  0.06 [11.8  0.7]
Linagliptin 5 mg þ empagliﬂozin 25 mg 134 1.19  0.06 [13.1  0.7]
Linagliptin 5 mg 128 0.70  0.06 [7.6  0.7]
Empagliﬂozin 10 mg 137 0.66  0.06 [7.2  0.7]
Empagliﬂozin 25 mg 140 0.62  0.06 [6.8  0.7]
Rosenstock et al,197 2015 24 wk Metformin Saxagliptin 5 mg þ dapagliﬂozin 10 mg 179 1.47  0.08d [16.1  0.9]
Saxagliptin 5 mg 176 0.88  0.08 [9.6  0.9]
Dapagliﬂozin 10 mg 179 1.20  0.08 [13.1  0.9]
Mathieu et al,198 2015 24 wk Metformin Dapagliﬂozin 10 mg þ saxagliptin 5 mg 146 0.82d  0.07 [9.0d  0.8]
Placebo þ saxagliptin 129 0.10  0.07 [1.1  0.8]
Matthaei et al,199 2015 24 wk Metformin Saxagliptin þ dapagliﬂozin 10 mg 139 0.51d (0.63 to 0.39)
[5.6d (6.9 to 4.3)]
Placebo þ dapagliﬂozin 10 mg 149 0.16d (0.28 to 0.04)
[1.7d (3.1 to 0.04)]
Mathieu et al,200 2016 52 wk Metformin Dapagliﬂozin 10 mg þ saxagliptin 5 mg 160 0.74d (0.90 to 0.57)
[8.1d (9.8 to 6.2)]
Placebo þ saxagliptin 5 mg 160 þ0.07d (0.13 to þ0.27)
[0.8d (1.4 to 3.0)]
Jabbour et al,201 2014 24 wk  Metformin Dapagliﬂozin 10 mg þ sitagliptin
100 mg
223 0.5 (0.6 to 0.4)e
[4.9 (6.0 to 3.8)]
Placebo þ sitagliptin 100 mg 224 0.0 (0.1 to þ0.1)
[þ0.4 (0.7 to þ1.5)]
GLP-1RA þ SGLT2i
Frías et al,202 2016 (DURATION-8) 28 wk Metformin Exenatide 2 mg QW þ dapagliﬂozin
10 mg every day
228 2.0 (2.1 to 1.8)
[21.9 (23.0 to 19.7)]
Exenatide 2 mg QW 227 1.6 (1.8 to 1.4)
[17.5 (19.7 to 15.3)]
Dapagliﬂozin 10 mg every day 230 1.4 (1.6 to 1.2)
[15.3 (17.5 to 13.1)]
aA1C ¼ glycated hemoglobin; DPP-4i ¼ dipeptidyl peptidase-4 inhibitor; DURATION-8 ¼ Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once
Weekly-8; GLP-1RA ¼ glucagon-like peptide-1 receptor agonist; QW ¼ once weekly; SGLT2i ¼ sodium-glucose cotransporter 2 inhibitor.
bData are presented as mean  standard error or mean (95% CI).
cDosing of DPP-4i and SGLT2i was once daily in all DPP-4i þ SGLT2i studies.
dAdjusted mean.
eLast observation carried forward analysis.
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Downloadcombination of an SGLT2i and either aDPP-4i or
a GLP-1RA (Table 3).195-202
Combination of DPP-4i and SGLT2i
To our knowledge, only 1 post hoc analysis
has examined the effect of 1 of these combina-
tion treatments on glucagon in patients with
T2D.117 Glucagon levels increased approxi-
mately 10% after a liquid meal tolerance test
with dapaglifozin treatment but did not
increase with saxagliptin or the combination
of saxagliptin and dapagliﬂozin. Interestingly,
the change in glucagon levels did not correlate
with changes in A1C levels.
Several large clinical studies have demon-
strated that the combination of a DPP-4i and
an SGLT2i improves glycemic control in patients
with T2D (Table 3).117,195-201 In each study, the
DPP-4i/SGLT2i combination resulted in a
greater A1C decrease than each drug alone:
this was true for the combinations of linagliptin
and empagliﬂozin,195,196 saxagliptin and dapa-
gliﬂozin,197-200 and sitagliptin and dapagliﬂo-
zin.200 Notably, although the combination of
linagliptin and empagliﬂozin195,196 and the
combination of saxagliptin and dapagliﬂozin197
resulted in greater A1C decreases than the indi-
vidual drugs and a signiﬁcant increase in the
proportion of patients attaining a target A1C of
less than 7.0%, in each case, the reductions in
A1C were less than additive.195-197
Combination of GLP-1RA and SGLT2i
Similar to the results from studies of DPP-4i/
SGLT2i combinations, GLP-1RA/SGLT2i com-
bination treatment was more effective than
either drug alone in reducing glucose
(Table 3); however, none of these studies
reported glucagon results.
The combination of a GLP-1RA and an
SGLT2i has, to our knowledge, been studied in
only 1 phase 3 trial. In theDURATION (Diabetes
Therapy Utilization: Researching Changes in
A1C, Weight and Other Factors Through Inter-
vention with Exenatide Once Weekly)-8 study,
the combination of exenatide once weekly and
dapagliﬂozin signiﬁcantly reduced A1C levels
from baseline compared with either drug alone,
although the effects were not additive.202
Results from the DURATION-8 study are
consistent with ﬁndings from previous small
studies and post hoc analyses of GLP-1RA/
SGLT2i combinations in T2D.203-205 In eachMayo Clin Proc. n February 201
ed for Anonymous User (n/a) at BS - University of Copenhagen from 
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to a GLP-1RA augmented A1C reductions
compared with the GLP-1RA alone. Similarly,
the combination of daily dapagliﬂozin and
exenatide once weekly was signiﬁcantly more
effective than placebo in improving body
weight and reducing the risk of prediabetes
than either drug alone.206 Ongoing large clin-
ical studies are examining the effects of adding
liraglutide to canagliﬂozin (NCT02324842)207
or dulaglutide to SGLT2is (AWARD-10 [A
Study of Dulaglutide in Participants with
Type 2 Diabetes Mellitus]; NCT02597049).208
Antagonism of the Glucagon Receptor
Antagonism of the glucagon receptor is being
investigated in another approach for treating
T2D.209 Inhibiting glucagon-induced hepatic
glucose production should, in theory, effec-
tively decrease both fasting and postprandial
hyperglycemia.4 In a murine model of T2D,
treatment with a glucagon receptor antagonist
normalized plasma glucose and A1C levels to
within nondiabetic ranges.210,211 Phase 2 clin-
ical studies have demonstrated reduced glyce-
mia in patients with T2D treated with
2 glucagon receptor antagonists,
LY2409021212 and PF-06291874.213 Despite
good effect on glycemic end points, no drug
in this class has reached the market for the
treatment of T2D. This may be a consequence,
in part, of observations that glucagon receptor
antagonism results in elevation of liver transam-
inases,4,212-215 liver fat,216,217 body weight,4,214
systolic blood pressure,215 low-density lipopro-
tein cholesterol levels,214,215 and alpha-cell hy-
perplasia.209 The mechanisms for these side
effects have been investigated, and though yet
unknown, the mechanism for the increase in
transaminase levels might be a result of in-
creases in hepatic fat content (triglycerides).213
Glucagon receptor antagonists have been asso-
ciated with increased cholesterol absorption
from the gut.218
Glucagon Receptor/GLP-1 Receptor
Coagonists
Another emerging therapeutic strategy for the
treatment of T2D and associated obesity that
capitalizes on the underlying pathophysiology
of glucagon is coagonism of the glucagon and
GLP-1 receptors by a single molecule, of which
there are now several examples with8;93(2):217-239 n https://doi.org/10.1016/j.mayocp.2017.12.003
www.mayoclinicproceedings.org
ClinicalKey.com by Elsevier on January 29, 2019.
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ROLE OF GLUCAGON IN TYPE 2 DIABETESexperimental evidence in rodent models.219-222
Readers are directed to the excellent review by
Müller et al3 and references therein for a fuller
discussion than space allows here.CONCLUSION
To normalize metabolic control of glucose in
the treatment of T2D, support has increased
for targeting not only abnormalities in insulin
secretion but also dysfunctional glucagon
secretion. Glucagon is a key regulator of
normal fuel metabolism, and both fasting
and postprandial hyperglucagonemia make
substantial contributions to the fasting hyper-
glycemia and postprandial glucose excursions
that characterize T2D. Because patients with
T2D have defects in glucagon control,
improved restoration of metabolic control by
therapies that also suppress glucagon,
including DPP-4is and GLP-1RAs, would be
beneﬁcial. Future studies should focus on
how novel strategies such as glucagon antago-
nism, glucagon/GLP-1 receptor coagonism, or
combining DPP-4is or GLP-1RAs with
SGLT2is can best control both insulin and
glucagon in patients with T2D.ACKNOWLEDGMENTS
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